

June 3, 2024  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Notice of Appointment of Corporate Officer

**TOKYO, Japan, June 3, 2024** -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, the “Company” or “SymBio”) today announced the appointment of a corporate officer by extraordinary meeting of the Board of Directors held on May 31, 2024.

### Appointment of Corporate Officer

Effective June 1, 2024, we have appointed Mr. Shigetaka Natsukuri as Corporate Officer, CFO and Investor Relations (IR). Mr. Natsukuri has a wealth of knowledge and experience in finance, including experience at a Japanese general trading company, where he was seconded to a newly established group company, experience at a domestic branch office and in investor relations. He introduced financing for two foreign subsidiaries and was stationed overseas twice. After returning to Japan, he worked as the head of treasury of a major Japanese pharmaceutical company, where he raised a large amount of funds.

Statement from Mr. Shigetaka Natsukuri: "I feel honored to accept the role of Corporate Officer, CFO and Investor Relations. In order to ensure the successful development and commercialization of the antiviral drug brincidofovir ("BCV"), which is our business objective, and to ensure future growth. I will lead the development of our financial goals and strategy, using my experience in finance, fundraising, and overseas assignments to ensure that our fundraising activities with respect to both Japan and overseas are executed in accordance with our financial plan, and to ensure the Company's financial targets are achieved.

Statement from Mr. Fuminori Yoshida, President and CEO of SymBio: "For us, the successful development and commercialization of BCV means the globalization of our business. With Mr. Natsukuri's knowledge and experience in finance and his overseas experience, we expect him to be a strong driving force for the globalization of our business."

1. Newly appointed Corporate Officer

Name	Title
Shigetaka Natsukuri	Corporate Officer and CFO, and IR

2. Date of Appointment: June 1, 2024

3. Profile of the newly appointed Corporate Officer

	Marubeni Corporation Extensive career in finance, including serving as Chief Financial Officer of Marubeni Hong Kong & South China Ltd., General Manager of Dusseldorf Branch of Marubeni Europe B.V, and Managing Director of Marubeni International (Europe) Ltd.
April 2023 ~ May 2024	Astellas Pharma Inc. Head of Japan Treasury
June 2024	Joined Symbio Pharmaceuticals Limited

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125